Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines

Journal of Infectious Diseases

Volumn 194, Issue 12, 2006, Pages 1625-1627

  Robinson, Harriet L ^a   Weinhold, Kent J ^b  

^a EMORY UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE ESCALATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; NOTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROTYPE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION; VIRUS RECOMBINANT;

AIDS VACCINES; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HIV; HIV INFECTIONS; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES; VACCINATION; VACCINES, SYNTHETIC;

EID: 33845442886     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509263     Document Type: Note

References (20)

1. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-49 (in this issue).
2. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-60 (in this issue).
3. Klausner RD, Fauci AS, Corey L, et al. Medicine: the need for a global HIV vaccine enterprise. Science 2003; 300:2036-9.
4. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43:500-11.
5. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol 2002; 2:239-50.
6. Letvin NL. Progress toward an HIV vaccine. Annu Rev Med 2005; 56:213-23.
7. Chakrabarti BK, Kong WP, Wu BY, et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002; 76:5357-68.
8. Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003; 77:12764-72.
9. Zuniga R, Lucchetti A, Galvan P, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006; 80:3122-5.
10. Edwards HH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002; 76:2298-305.
11. Barouch DH, Yang ZY, Kong WP, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005;79:8828-34.
12. Graham B. Safety and immunogenicity of a multiclade HIV-1 recombinant adenovirus vaccine boost in prior recipients of a multiclade HIV-1 DNA vaccine [abstract 9]. In: AIDS Vaccine 2005 (Montreal). 2005.
13. Cohen J. Hedged bet: an unusal AIDS vaccine trial. Science 2005;309:1003.
14. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-72.
15. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive trial. J Infect Dis 2005; 191:666-77.
16. Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science 2002; 295:1616-7.
17. Shiver JW, Fu T, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 2002; 415:331-5.
18. Letvin NL, Huang Y, Chakrabarti BK, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490-7.
19. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-3.
20. International AIDS Vaccine Initiative (IAVI). Preventive HIV Vaccine Trials. IAVI, 2006.